The post-hoc look covered 2,309 women over 68 weeks versus 3% on placebo. BMO also flags Ozempic losing US share as Awiqli gains a label for kids 10 and up.
Recap by typeshit. Full story at ad-hoc-news.de.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
16:22
After three years on tirzepatide, Simply Sunshine shares what she has learned along the way and answers whether she would start the drug again.
Christoffer Røst Benneballe of Nordea argues Novo Nordisk needs the Wegovy pill as fresh pipeline growth while Eli Lilly's competition heats up.
Loading…